Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18874058 | 0.94 | KMT2A (0.44) | KMT2ATLR7HSD11B1SIGMAR1HTR7 | |
| SCHEMBL7907323 | 0.94 | KMT2A (0.46) | KMT2ATLR7HSD11B1SIGMAR1PHGDH | |
| SCHEMBL7899320 | 0.91 | HSD11B1 (0.48) | KMT2ATLR7HSD11B1SIGMAR1PHGDH | |
| SCHEMBL13088144 | 0.91 | HSD11B1 (0.48) | KMT2ATLR7HSD11B1SIGMAR1PHGDH | |
| SCHEMBL23732169 | 0.89 | KMT2A (0.46) | KMT2ATLR7HSD11B1SIGMAR1PHGDH | |
| SCHEMBL13462619 | 0.86 | KMT2A (0.43) | KMT2ATLR7 | |
| SCHEMBL7472619 | 0.85 | KMT2A (0.39) | KMT2ATLR7HSD11B1SIGMAR1HTR7 | |
| SCHEMBL1203139 | 0.85 | KMT2A (0.39) | KMT2ATLR7HSD11B1HTR7TLR9 | |
| SCHEMBL13548824 | 0.85 | KMT2A (0.50) | KMT2AHSD11B1OPRM1OPRL1 | |
| SCHEMBL7907325 | 0.84 | KMT2A (0.49) | KMT2ATLR7HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871789-B2 | Method of preventing or treating viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | KDM1B, KDM1A, KDM2A | KMT2A 37/4885TLR7 1269/4885HSD11B1 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.